Dataset Information

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

ABSTRACT: Cancer is a genetic disease, but two patients rarely have identical genotypes. Similarly, patients differ in their clinicopathological parameters, but how genotypic and phenotypic heterogeneity are interconnected is not well understood. Here we build statistical models to disentangle the effect of 12 recurrently mutated genes and 4 cytogenetic alterations on gene expression, diagnostic clinical variables and outcome in 124 patients with myelodysplastic syndromes. Overall, one or more genetic lesions correlate with expression levels of ~20% of all genes, explaining 20-65% of observed expression variability. Differential expression patterns vary between mutations and reflect the underlying biology, such as aberrant polycomb repression for ASXL1 and EZH2 mutations or perturbed gene dosage for copy-number changes. In predicting survival, genomic, transcriptomic and diagnostic clinical variables all have utility, with the largest contribution from the transcriptome. Similar observations are made on the TCGA acute myeloid leukaemia cohort, confirming the general trends reported here.

SUBMITTER: Gerstung M

PROVIDER: S-EPMC4338540 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Gerstung Moritz M Pellagatti Andrea A Malcovati Luca L Giagounidis Aristoteles A Porta Matteo G Della MG Jädersten Martin M Dolatshad Hamid H Verma Amit A Cross Nicholas C P NC Vyas Paresh P Killick Sally S Hellström-Lindberg Eva E Cazzola Mario M Papaemmanuil Elli E Campbell Peter J PJ Boultwood Jacqueline J

Nature communications 20150109

Cancer is a genetic disease, but two patients rarely have identical genotypes. Similarly, patients differ in their clinicopathological parameters, but how genotypic and phenotypic heterogeneity are interconnected is not well understood. Here we build statistical models to disentangle the effect of 12 recurrently mutated genes and 4 cytogenetic alterations on gene expression, diagnostic clinical variables and outcome in 124 patients with myelodysplastic syndromes. Overall, one or more genetic les ...[more]

PMID: 25574665

Similar Datasets

Project description:BackgroundSeveral gene sets for prediction of breast cancer survival have been derived from whole-genome mRNA expression profiles. Here, we develop a statistical framework to explore whether combination of the information from such sets may improve prediction of recurrence and breast cancer specific death in early-stage breast cancers. Microarray data from two clinically similar cohorts of breast cancer patients are used as training (n?=?123) and test set (n?=?81), respectively. Gene sets from eleven previously published gene signatures are included in the study.Principal findingsTo investigate the relationship between breast cancer survival and gene expression on a particular gene set, a Cox proportional hazards model is applied using partial likelihood regression with an L2 penalty to avoid overfitting and using cross-validation to determine the penalty weight. The fitted models are applied to an independent test set to obtain a predicted risk for each individual and each gene set. Hierarchical clustering of the test individuals on the basis of the vector of predicted risks results in two clusters with distinct clinical characteristics in terms of the distribution of molecular subtypes, ER, PR status, TP53 mutation status and histological grade category, and associated with significantly different survival probabilities (recurrence: p?=?0.005; breast cancer death: p?=?0.014). Finally, principal components analysis of the gene signatures is used to derive combined predictors used to fit a new Cox model. This model classifies test individuals into two risk groups with distinct survival characteristics (recurrence: p?=?0.003; breast cancer death: p?=?0.001). The latter classifier outperforms all the individual gene signatures, as well as Cox models based on traditional clinical parameters and the Adjuvant! Online for survival prediction.ConclusionCombining the predictive strength of multiple gene signatures improves prediction of breast cancer survival. The presented methodology is broadly applicable to breast cancer risk assessment using any new identified gene set.

Dataset Information

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Publications

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets